Komrokji R - Search Results

1

Abel GA, Hebert D, Lee C, Rollison D, Gillis N, Komrokji R, Foran JM, Liu JJ, Al Baghdadi T, Deeg J, Gore S, Saber W, Wilson S, Otterstatter M, Thompson J, Borchert C, Padron E, DeZern A, Cella D, Sekeres MA. Abel GA, et al. Among authors: komrokji r. Blood Adv. 2023 Jul 25;7(14):3506-3515. doi: 10.1182/bloodadvances.2022009000. Blood Adv. 2023. PMID: 37146263 Free PMC article. Clinical Trial.

2

Outcome of patients with myelodysplastic syndromes in the Veterans Administration population.

Komrokji RS, Matacia-Murphy GM, Al Ali NH, Beg MS, Safa MM, Rollison DE, List AF. Komrokji RS, et al. Leuk Res. 2010 Jan;34(1):59-62. doi: 10.1016/j.leukres.2009.03.022. Epub 2009 Apr 14. Leuk Res. 2010. PMID: 19368972

3

NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes.

Greenberg PL, Attar E, Bennett JM, Bloomfield CD, De Castro CM, Deeg HJ, Foran JM, Gaensler K, Garcia-Manero G, Gore SD, Head D, Komrokji R, Maness LJ, Millenson M, Nimer SD, O'Donnell MR, Schroeder MA, Shami PJ, Stone RM, Thompson JE, Westervelt P; National Comprehensive Cancer Network. Greenberg PL, et al. Among authors: komrokji r. J Natl Compr Canc Netw. 2011 Jan;9(1):30-56. doi: 10.6004/jnccn.2011.0005. J Natl Compr Canc Netw. 2011. PMID: 21233243 Free PMC article.

4

Biology and treatment of the 5q- syndrome.

Padron E, Komrokji R, List AF. Padron E, et al. Among authors: komrokji r. Expert Rev Hematol. 2011 Feb;4(1):61-9. doi: 10.1586/ehm.11.2. Expert Rev Hematol. 2011. PMID: 21322779 Review.

5

Management of lower-risk myelodysplastic syndromes: the art and evidence.

Komrokji RS, Sekeres MA, List AF. Komrokji RS, et al. Curr Hematol Malig Rep. 2011 Jun;6(2):145-53. doi: 10.1007/s11899-011-0086-x. Curr Hematol Malig Rep. 2011. PMID: 21442178 Review.

6

Telomere length in myelodysplastic syndromes.

Rollison DE, Epling-Burnette PK, Park JY, Lee JH, Park H, Jonathan K, Cole AL, Painter JS, Guerrier M, Meléndez-Santiago J, Fulp W, Komrokji R, Lancet J, List AF. Rollison DE, et al. Among authors: komrokji r. Leuk Lymphoma. 2011 Aug;52(8):1528-36. doi: 10.3109/10428194.2011.568648. Epub 2011 Jun 3. Leuk Lymphoma. 2011. PMID: 21635204 Free PMC article.

7

Cutaneous manifestations in CMML: Indication of disease acceleration or transformation to AML and review of the literature.

Mathew RA, Bennett JM, Liu JJ, Komrokji RS, Lancet JE, Naghashpour M, Messina JL, List AF, Moscinski LC, Zhang L. Mathew RA, et al. Leuk Res. 2012 Jan;36(1):72-80. doi: 10.1016/j.leukres.2011.05.003. Epub 2011 Jul 22. Leuk Res. 2012. PMID: 21782240 Review.

8

Validation of the MD Anderson Prognostic Risk Model for patients with myelodysplastic syndrome.

Komrokji RS, Corrales-Yepez M, Al Ali N, Kharfan-Dabaja M, Padron E, Fields T, Lancet JE, List AF. Komrokji RS, et al. Cancer. 2012 May 15;118(10):2659-64. doi: 10.1002/cncr.26567. Epub 2011 Sep 28. Cancer. 2012. PMID: 21956402 Free article.

9

The 5q- syndrome: biology and treatment.

Padron E, Komrokji R, List AF. Padron E, et al. Among authors: komrokji r. Curr Treat Options Oncol. 2011 Dec;12(4):354-68. doi: 10.1007/s11864-011-0165-1. Curr Treat Options Oncol. 2011. PMID: 21964863

10

Expansion of effector memory regulatory T cells represents a novel prognostic factor in lower risk myelodysplastic syndrome.

Mailloux AW, Sugimori C, Komrokji RS, Yang L, Maciejewski JP, Sekeres MA, Paquette R, Loughran TP Jr, List AF, Epling-Burnette PK. Mailloux AW, et al. Among authors: komrokji rs. J Immunol. 2012 Sep 15;189(6):3198-208. doi: 10.4049/jimmunol.1200602. Epub 2012 Aug 8. J Immunol. 2012. PMID: 22875800 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

360 results

Search Page